1. Resources
  2. Citations Library

Citation Details

You are viewing citation details. You can save or export citation(s) below, access an article, or start a new search.

1–1 of 1 record found matching your query:

Headers act as filters

      1. Author :
        Xu, Junjie; Lin, Hui; Li, Gonghui; Sun, Yin; Shi, Liang; Ma, Wen-Lung; Chen, Jiang; Cai, Xiujun; Chang, Chawnshang
      2. Title :
      3. Type :
        Journal Article
      4. Year :
        2017
      5. Publication :
        International Journal of Cancer
      6. Products :
      7. Volume :
        140
      8. Issue :
        3
      9. Page Numbers :
        N/A
      10. Research Area :
        N/A
      11. Keywords :
        Sorafenib; ASC-J9®; hepatocellular carcinoma; synergism; IVIS; IVIS BLI in vivo
      12. Abstract :
        Sorafenib is currently used as a standard treatment to suppress the progression of hepatocellular carcinoma (HCC), especially in advanced stages. However, patients who receive Sorafenib treatment eventually develop resistance without clear mechanisms. There is a great need for better efficacy of Sorafenib treatment in combination with other therapies. Here, we demonstrated that the treatment combining Sorafenib with ASC-J9® could synergistically suppress HCC progression via altering cell-cycle regulation, apoptosis and invasion. Mechanism dissection suggests that while Sorafenib impacts little or even slightly increases the activated/phosphorylated STAT3 (p-STAT3), a key stimulator to promote the HCC progression, adding ASC-J9® significantly suppresses the p-STAT3 expression and its downstream genes including CCL2 and Bcl2. Interrupting these signals via constitutively active STAT3 partially reverses the synergistic suppression of Sorafenib-ASC-J9® combination on HCC progression. In vivo studies further confirmed the synergistic effect of Sorafenib-ASC-J9® combination. Together, these results suggest the newly developed Sorafenib-ASC-J9® combination is a novel therapy to better suppress HCC progression.
      13. URL :
        http://dx.doi.org/10.1002/ijc.30446 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215679/pdf/IJC-140-705.pdf
      14. Call Number :
        PKI @ catherine.lautenschlager @ 12549
      15. Serial :
        13618